Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia

NCT07192237 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Phase 2 Study
Blinatumomab
Acute Lymphoblastic Leukemia

Interventions

DRUG: Blinatumomab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]